Key Takeaways
- Krystal Biotech’s Vyjuvek, Regeneron’s Lynozyfic, Takeda’s Deqsiga and Accord Healthcare’s Accord Trabectedin have been backed for pan-EU approval by the European Medicines Agency
Vyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be...